Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2896 AL 2910

Comparison of two infrared devices in their effectiveness in reducing symptoms associated with RLS

Mitchell UH, Johnson AW, Myrer B.

Physiother Theory Pract. 2011 Jul;27(5):352-9. doi: 10.3109/09593985.2010.502210. Epub 2010 Oct 16.

Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood

Montagna P, Hornyak M, Ulfberg J, Hong SB, Koester J, Crespi G, Albrecht S.

Sleep Med. 2011 Jan;12(1):34-40. doi: 10.1016/j.sleep.2010.08.005. Epub 2010 Oct 20.

Restless legs syndrome and near-infrared light: An alternative treatment option

Mitchell UH, Myrer JW, Johnson AW, Hilton SC.

Physiother Theory Pract. 2011 Jul;27(5):345-51. doi: 10.3109/09593985.2010.511440. Epub 2010 Oct 26.

Efficacy, safety and dose-response of pramipexole in Japanese patients with primary restless legs syndrome: randomized trial

Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T.

Neuropsychobiology. 2011;63(1):35-42. doi: 10.1159/000322289. Epub 2010 Nov 9.

Restless legs syndrome due to aripiprazole

Bolaños-Vergaray J, Obaya JC, Gonzalez R, Echeverri C, Piquer P.

Eur J Clin Pharmacol. 2011 May;67(5):539-40. doi: 10.1007/s00228-010-0952-9. Epub 2010 Nov 21.

Phantom restless legs syndrome in a patient with unilateral above knee amputation

Dempewolf S, Bunten S, Happe S.

Sleep Med. 2011 Jan;12(1):105-6. doi: 10.1016/j.sleep.2010.08.003. Epub 2010 Dec 8.

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study

Benes H, Mattern W, Peglau I, Dreykluft T, Bergmann L, Hansen C, Kohnen R, Banik N, Schoen SW, Hornyak M.

J Neurol. 2011 Jun;258(6):1046-54. doi: 10.1007/s00415-010-5879-7. Epub 2010 Dec 28.

Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome

Navacerrada F, González-Alonso MR, Alonso-Navarro H, Pilo-de-la-Fuente B, Plaza-Nieto JF, Jiménez-Jiménez FJ.

Eur J Neurol. 2011 Jun;18(6):e65. doi: 10.1111/j.1468-1331.2010.03317.x. Epub 2010 Dec 29.

The cholinergic system and Parkinson disease

Bohnen NI, Albin RL.

Behav Brain Res. 2011 Aug 10;221(2):564-73. doi: 10.1016/j.bbr.2009.12.048. Epub 2010 Jan 7.

The reliability of transcranial duplex scanning in parkinsonian patients: comparison of different observers and ultrasound systems

Vlaar A, Tromp SC, Weber WE, Hustinx RM, Mess WH.

Ultraschall Med. 2011 Jan;32 Suppl 1:S83-8. doi: 10.1055/s-0028-1109945. Epub 2010 Jan 21.

Development of nociceptin receptor (NOP) agonists and antagonists

Mustazza C, Bastanzio G.

Med Res Rev. 2011 Jul;31(4):605-48. doi: 10.1002/med.20197. Epub 2010 Jan 22.

Glycogen synthase kinase 3β and its phosphorylated form (Y216) in the paraquat-induced model of parkinsonism

Songin M, Strosznajder JB, Fitał M, Kuter K, Kolasiewicz W, Nowak P, Ossowska K.

Neurotox Res. 2011 Jan;19(1):162-71. doi: 10.1007/s12640-010-9153-7. Epub 2010 Feb 9.

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS

Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ.

J Clin Pharmacol. 2011 Jan;51(1):66-74. doi: 10.1177/0091270010363476. Epub 2010 Mar 10.

Influence of left versus right hemibody onset Parkinson's disease on cardiovascular control

Foster PS, Drago V, Harrison DW, Skidmore F, Crucian GP, Heilman KM.

Laterality. 2011 Mar;16(2):164-73. doi: 10.1080/13576500903483507. Epub 2010 Mar 19.

Inhibition of hydrogen sulfide generation contributes to 1-methy-4-phenylpyridinium ion-induced neurotoxicity

Tang XQ, Fan LL, Li YJ, Shen XT, Zhuan YY, He JQ, Xu JH, Hu B, Li YJ.

Neurotox Res. 2011 Apr;19(3):403-11. doi: 10.1007/s12640-010-9180-4. Epub 2010 Apr 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias